US Drug Pricing Policy Threatens European Pharma Innovation

The United States, under the Trump administration, is aggressively pursuing a policy to drastically lower the prices of imported drugs, aiming to make them the cheapest worldwide. This strategy presents a significant challenge to the European pharmaceutical industry, raising concerns about innovation and global competitiveness. The U.S. demands are clear: lower prices for the American market and a relocation of production and research to the United States. This reality is already unfolding, with pharmaceutical firms entering into agreements with the U.S. administration. The implications for Europe, including Poland, are profound. A primary effect will be a shift in drug registration priorities, meaning that advanced therapies could become available later in Europe. While this is a gradual process, the U.S. objective is unambiguous: drugs needed by Americans should be manufactured in America. Currently, a substantial portion of drugs sold in the U.S. are produced in European factories. The critical question is whether these drugs will remain accessible and affordable for Europeans in the future. Will European firms succumb to the pressure and move their operations to the U.S.? We are already witnessing this shift. The success of the U.S. policy, which dominates the global market, will inevitably come at Europe's expense. The pharmaceutical sector is a cornerstone of the EU's industry, known for its innovation and contribution to GDP. The risk of losing this 'pearl' due to U.S. policy is real. Over the past two decades, investments in pharmaceutical innovation in Europe have declined by 25%, and funding for clinical trials has halved. While Poland has bucked this trend, becoming a major global hub for clinical research, the broader European landscape faces significant headwinds.